Table 3.

Patient characteristics.

	Patients without joint involvement (n = 46)	Patients with joint involvement (n = 14)	P
Race/Ethnicity	European (n = 60)
Country of origin	Spain (n = 60)
Age at the end of follow-up, y	8.5 (6-14)	18 (12-19)	0.003
Age at start of prophylaxis, y	1 (1-1)	3 (2-4.3)	<0.001
<3 y, n	46
<2 y, n	42	8
≥3 y, n	0	06
Age at onset of joint involvement, years (HJHS 2.1 or HEAD-US ≥1)	-	12 (3-18)

Note: Values are listed as median (IQR) unless otherwise specified.